Needham & Company Maintains a 'Buy' on Hi Tech Pharmacal (HITK); Weakness Related to FDA Event a Buying Opportunity
Tweet Send to a Friend
Needham & Company maintains a 'Buy' rating on Hi Tech Pharmacal (Nasdaq: HITK), price target $32.
Needham analyst says, "HITK ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Needham analyst says, "HITK ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
